SUPN - Supernus Pharmaceuticals, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
54.25
-1.85 (-3.30%)
As of 1:12PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close56.10
Open56.05
Bid54.40 x 800
Ask54.45 x 1000
Day's Range52.95 - 56.05
52 Week Range33.30 - 59.05
Volume687,924
Avg. Volume731,722
Market Cap2.81B
Beta1.70
PE Ratio (TTM)39.51
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Total Returns and Sector Exposure for Growth Indexes
    Market Realist2 hours ago

    Total Returns and Sector Exposure for Growth Indexes

    If we dig into the S&P 500 and the S&P Growth indexes, we can see that they have the highest exposure to information technology (or IT). The S&P 500 Growth index generated a three-year and five-year annualized return of 13.2% and 15.2%, respectively. These returns compare to the S&P 500 (SPY) at 10.7% and 13% for the same timespan, respectively. The S&P 500 Growth index generated YTD (year-to-date) return of 5.5%, compared to the S&P 500 at 1.5%. The S&P 500 Growth has 41% exposure to information technology, compared to the S&P 500 at 24.8%. ...

  • Breakout Watch: Biotech Stock With 172% Growth Enters Buy Zone
    Investor's Business Daily5 days ago

    Breakout Watch: Biotech Stock With 172% Growth Enters Buy Zone

    Leading biotech stock and IBD 50 member Ligand Pharmaceuticals is in a buy zone after reporting 172% earnings growth.

  • Implied Volatility Surging for Supernus (SUPN) Stock Options
    Zacks6 days ago

    Implied Volatility Surging for Supernus (SUPN) Stock Options

    Supernus (SUPN) needs investors to pay close attention to the stock based on moves in the options market lately.

  • 6 Ways To Play Biotechs As Small Stocks Score Big Gains
    Investor's Business Daily10 days ago

    6 Ways To Play Biotechs As Small Stocks Score Big Gains

    The biotech group is trying to climb past its 50-day moving average, so it may be a good time to keep an eye on biotech ETFs.

  • Thomson Reuters StreetEvents10 days ago

    Edited Transcript of SUPN earnings conference call or presentation 9-May-18 1:00pm GMT

    Q1 2018 Supernus Pharmaceuticals Inc Earnings Call

  • Associated Press13 days ago

    Supernus: 1Q Earnings Snapshot

    On a per-share basis, the Rockville, Maryland-based company said it had net income of 49 cents. The results beat Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment ...

  • 3 Top Biotech Stocks to Buy Right Now
    Motley Foollast month

    3 Top Biotech Stocks to Buy Right Now

    There's good reason to consider buying shares in these biotech companies soon.

  • MarketWatchlast month

    Harry Boxer’s biotech-stock breakouts to watch

    In focus: uniQure, Supernus Pharmaceuticals and ViewRay.

  • Analysts’ Recommendations for AbbVie in April 2018
    Market Realistlast month

    Analysts’ Recommendations for AbbVie in April 2018

    In April 2018, the FDA notified AbbVie (ABBV) and Neurocrine Biosciences that it would need more time to review liver function test data provided by AbbVie with its new drug application for Elagolix for the management of endometriosis-associated pain, extending its Prescription Drug User Fee Act goal date by three months to 3Q18. In 4Q17, the FDA granted Elagolix priority review. In clinical trials, Elagolix was evaluated for safety and efficacy in ~1,700 women with moderate-to-severe endometriosis-related pain.

  • See what the IHS Markit Score report has to say about Supernus Pharmaceuticals Inc.
    Markitlast month

    See what the IHS Markit Score report has to say about Supernus Pharmaceuticals Inc.

    Short interest is moderate for SUPN with between 5 and 10% of shares outstanding currently on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Over the last one-month, outflows of investor capital in ETFs holding SUPN totaled $776 million.

  • Top 3 Growth Stocks For The Month
    Simply Wall St.last month

    Top 3 Growth Stocks For The Month

    Investors tend to look for stocks that have a strong future outlook. Why invest in something that will grow slower than the rest of the market? In terms of profitabilityRead More...

  • See what the IHS Markit Score report has to say about Supernus Pharmaceuticals Inc.
    Markitlast month

    See what the IHS Markit Score report has to say about Supernus Pharmaceuticals Inc.

    Supernus Pharmaceuticals Inc NASDAQ NMS:SUPN

  • Here’s What Drove Supernus Pharmaceuticals Stock in March 2018
    Market Realistlast month

    Here’s What Drove Supernus Pharmaceuticals Stock in March 2018

    Supernus Pharmaceuticals (SUPN) stock has risen 18.2%, from $38.75 on March 1, 2018, to $45.80 on March 29, 2018. In its 2017 results announced on February 28, 2018, the company focused on developing and commercializing drugs targeted at treating central nervous system diseases. It reported a 41% year-over-year (or YoY) growth in fiscal 2017 revenues, which were about $300 million. It also reported earnings before income tax of around $100 million in 2017, which is a YoY rise of 100%. ...

  • Thomson Reuters StreetEvents2 months ago

    Edited Transcript of SUPN earnings conference call or presentation 28-Feb-18 2:00pm GMT

    Q4 2017 Supernus Pharmaceuticals Inc Earnings Call

  • American City Business Journals2 months ago

    Supernus getting Maryland incentives in HQ relocation, plans to add 160 jobs

    Now we know Maryland is helping out to the tune of more than $1.7 million. Maryland Gov. Larry Hogan announced Wednesday the state will provide $800,000 loan through the Maryland Economic Development Assistance Authority and Fund to assist with the move. Montgomery County is providing a $500,000 conditional grant through its Economic Development Fund, and Gaithersburg is providing a grant up to $400,000 through its Economic Development Opportunity Fund.

  • Supernus getting Maryland incentives in HQ relocation, plans to add 160 jobs
    American City Business Journals2 months ago

    Supernus getting Maryland incentives in HQ relocation, plans to add 160 jobs

    The company is moving from Rockville to Gaithersburg.

  • See what the IHS Markit Score report has to say about Supernus Pharmaceuticals Inc.
    Markit2 months ago

    See what the IHS Markit Score report has to say about Supernus Pharmaceuticals Inc.

    Short interest is moderate for SUPN with between 5 and 10% of shares outstanding currently on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices.

  • American City Business Journals2 months ago

    Supernus Pharmaceuticals inks deal for new, expanded headquarters

    After a year of surging growth, Supernus Pharmaceuticals Inc. is building out a new home double its current size. The Rockville biotech, which specializes in creating therapies for central nervous system diseases, is moving its headquarters to the Firstfield Life Science Cluster at 700 Quince Orchard Road in Gaithersburg, leasing approximately 119,000 square feet, according to a filing with the Securities and Exchange Commission. It's nearly 8 miles north on Interstate 270 from its current digs, at 1550 E. Gude Drive, where it occupies 44,500 square feet of laboratory and office space.

  • GuruFocus.com3 months ago

    Supernus Pharmaceuticals Inc (SUPN) Files 10-K for the Fiscal Year Ended on December 31, 2017

    Supernus Pharmaceuticals Inc (NASDAQ:SUPN) files its latest 10-K with SEC for the fiscal year ended on December 31, 2017.

  • Associated Press3 months ago

    Supernus beats Street 4Q forecasts

    On a per-share basis, the Rockville, Maryland-based company said it had profit of 26 cents. Earnings, adjusted for pretax expenses, came to 44 cents per share. The results beat Wall Street expectations. ...

  • Benzinga3 months ago

    Supernus Pharmaceuticals Q4 Earnings Preview

    On Tuesday, Supernus Pharmaceuticals (NASDAQ: SUPN ) will release its latest earnings report. Decipher the announcement with Benzinga's help. Earnings and Revenue Supernus Pharmaceuticals EPS will likely ...

  • Top Growth Stocks To Buy
    Simply Wall St.3 months ago

    Top Growth Stocks To Buy

    Why invest in a stock whose growth outlook that lags behind the market? Investors looking for companies with extraordinary future prospects in terms of profitability and returns should look atRead More...

  • See what the IHS Markit Score report has to say about Supernus Pharmaceuticals Inc.
    Markit3 months ago

    See what the IHS Markit Score report has to say about Supernus Pharmaceuticals Inc.

    Short interest is moderate for SUPN with between 5 and 10% of shares outstanding currently on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. The net inflows of $664 million over the last one-month into ETFs that hold SUPN are among the lowest of the last year and appear to be slowing.

  • See what the IHS Markit Score report has to say about Supernus Pharmaceuticals Inc.
    Markit3 months ago

    See what the IHS Markit Score report has to say about Supernus Pharmaceuticals Inc.

    Supernus Pharmaceuticals Inc NASDAQ NMS:SUPN

  • American City Business Journals3 months ago

    See the D.C.-area stocks hit hardest in the last week

    Several D.C.-area publicly traded companies saw their stock prices hit in recent days as U.S. stock exchanges saw a widespread selloff Friday, continuing into Monday trading. In the worst stock market ...